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The aims of this study were to compare the prevalence of
the metabolic syndrome according to the WHO and NCEP
ATP III criteria in Korean adults, and to compare the
prevalence of the metabolic syndrome with the results in
previous Korean studies. The study comprised 1,230 subjects
(627 men, 603 women) aged 30-79 years (mean 52.4±10.3
years) who underwent medical check-up from April to June,
2001 in the Korea Association of Health (KAH). The preva-
lence of the metabolic syndrome according to the modified
WHO criteria was 21.8% of men and 19.4% of women.
However, the prevalence was increased 1.6 times (34.2%) in
men and 2.0 times (38.7%) in women using the modified
NCEP criteria. The prevalence of the metabolic syndrome has
varied widely according to differences in the criteria. Thus,
further studies are necessary to define the appropriate criteria
of the metabolic syndrome for Korean adults.
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INTRODUCTION
In 1988, Gerald Reaven reintroduced the con-
cept of syndrome X for the clustering of cardio-
vascular risk factors like glucose intolerance,
hypertension, high triglycerides, and low HDL
cholesterol.
1
In 1998, the World Health Organization (WHO)
proposed a working definition for this syndrome.
2
Then the National Cholesterol Education Program
(NCEP) proposed new criteria for this syndrome
in 2001, which is considered easier for clinical
application.
3
While the prevalence of obesity is lower in
Asian populations than in Western countries, the
health risks associated with obesity occur at a
lower body mass index (BMI) in Asian popula-
tions.
4-7 Thus new criteria to define overweight
and obesity for Asians in the Asia-Pacific Region
were proposed in 2000 by WHO.
8
The prevalence of the metabolic syndrome has
shown marked variation from different studies,
most likely because the criteria for the definition
of the metabolic syndrome have not been deter-
mined and because of ethnic differences.
9-13 In
Korea, limited studies are available about the
prevalence of the metabolic syndrome,
14-18 and
there are no appropriate diagnostic criteria which
consider the Korean ethnic character. Thus, the
aims of this study were, 1) to compare the pre-
valence of the metabolic syndrome according to
the WHO and NCEP ATP III criteria in Korean
adults, and 2) to compare the prevalence of the
metabolic syndrome with the results in previous
Korean studies.
MATERIALS AND METHODS
The Korean Metabolic Syndrome Study was
designed in 2001 as a prospective study, primarily
to investigate the metabolic syndrome as a risk
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factor for cardiovascular disease in the Korean
general population. From individuals partici-
pating in medical check-ups for the Korea Asso-
ciation of Health (KAH) from April to June, 2001,
1,230 subjects (627 men, 603 women) aged 30-79
years (mean 52.4±10.3 years) were included in the
present study.
Methods
After an overnight fast, fasting blood samples
were drawn from subjects to measure plasma
glucose, serum insulin, total cholesterol, HDL
cholesterol, and triglyceride concentrations.
Plasma glucose was measured with a glucose
oxidase method (Hitachi 747 automatic analyzer,
Hitachi, Tokyo). Glucose tolerance was assessed
according to the new American Diabetes Associa-
tion criteria. Thus, subjects with a fasting plasma
glucose 7.0 mmol/L (126 mg/dL) and/or use of
medications for diabetes were considered to have
diabetes, 6.1-6.9 mmol/L (110-125 mg/dL) to have
impaired fasting glucose (IFG), and < 6.1 mmol/
L (110 mg/dL) to have normal fasting glucose
(NFG).
Serum insulin concentrations were measured
with radioimmunoassay (Linco Research, Inc.,
Missouri, USA) with an interassay coefficient of
variation (CV) of 4%. This assay does not cross-
react with human pro-insulin (< 0.2%).
To obtain an estimate of insulin resistance, we
applied the homeostasis model assessment of
insulin resistance (HOMA-IR) using the following
formula: HOMA-IR=fasting insulin ( U/ml) μ ×
fasting plasma glucose (mmol/l)/22.5.
19 HOMA-
IR was not estimated in patients treated with
insulin.
Serum total cholesterol, HDL cholesterol, and
triglycerides were measured using an autoana-
lyzer with enzymatic colorimetric method (Hitachi
747, Hitachi, Tokyo). LDL cholesterol concentra-
tions were calculated using the Friedewald for-
mula.
20
Blood pressure was measured by using a
standard mercury sphygmomanometer after the
subject had been seated for at least 5 minutes.
BMI was calculated as weight (kg) divided by
the square of height (m
2) after body weight and
height were measured with subjects in light
clothing without shoes. Waist circumference was
measured with a soft tape on standing subjects
midway between the lowest rib and the iliac crest.
A standardized health questionnaire was com-
pleted by specially-trained nurses, covering the
subjects' past medical history, including current
and previous medication and smoking habits.
Definition of the metabolic syndrome according
to modified WHO definition
We used modified criteria of the 1999 WHO
definition for the metabolic syndrome.
2 We
excluded IGT because of the inconvenience and
cost of the oral glucose tolerance test. We used
HOMA-IR instead of the glucose disposal rate by
insulin clamp for insulin resistance. Microalbu-
minuria was excluded as a component of the
metabolic syndrome because of its low prevalence
(3-7%) in nondiabetic subjects.
11 We also used the
new criteria of BMI in the Asia-Pacific Region.
8
From these considerations, the modified WHO
definition required fasting glucose 6.1 mmol/L
(IFG or DM) or insulin resistance (HOMA-IR in
the top quartile of the non diabetic population)
plus at least two of the following: 1) obesity,
defined as a high BMI ( 25 kg/m
2) and/or a high
WHR ( 0.9 in men and 0.85 in women), 2)
dyslipidemia, defined as elevated triglyceride (
1.7 mmol/L (150 mg/dL)) and/or low HDL cho-
lesterol (< 0.9 mmol/L (35 mg/dL) in men and <
1.0 mmol/L (39 mg/dL) in women), and 3) hyper-
tension, defined as antihypertensive medication
and/or elevated blood pressure ( 140 mm Hg
systolic and/or 90 mmHg diastolic).
Definition of the metabolic syndrome according
to modified NCEP ATP III definition
We used the new criteria of waist circumference
in the Asia-Pacific Region instead of the original
criteria.
8 Thus, the modified NCEP definition
required at least three of the following: 1) in-
creased waist circumference (> 90 cm in men and
> 80 cm in women), 2) high triglycerides ( 1.7
mmol/L (150 mg/dL)), 3) low HDL cholesterol (<
1.04 mmol/L (40 mg/dL) in men and < 1.29
mmol/L (50 mg/dL) in women), 4) high blood
pressure ( 130/85 mmHg or current antihyper-Sung Hee Choi, et al.
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tensive medication), and 5) high fasting glucose
( 6.1 mmol/L (110 mg/dL) or current antidiabe-
tic medication).
3
Statistical analysis
The values are given as means±SD. The clinical
and metabolic characteristics of the study subjects
were compared by independent t-test, chi-square
test or Fisher's exact test between men and
women. The prevalence of the metabolic
syndrome and its components between sex and
age groups was compared by chi-square test or
Fisher's exact test. The statistical analyses were
performed with SPSS program for Windows (SPSS
Inc., Chicago, IL, USA). A p value < 0.05 was
considered statistically significant.
RESULTS
The clinical and metabolic characteristics of the
subjects are given in Table 1. Women were older
than men. The average levels of height, weight,
WC, and WHR were higher in men than in
women, but BMI was higher in women. FPG and
Table 1. Clinical and Metabolic Characteristics of the Subjects
Total Men Women
N 1,230 627 603
Age (years) 52.4 ± 10.3 51.3 ± 10.8 53.5 ± 9.6*
Height (cm) 162.0 ± 8.6 168.4 ± 5.7 155.3 ± 5.4*
Weight (kg) 64.7 ± 9.8 69.1 ± 8.9 60.1 ± 8.4*
BMI (kg/m
2) 24.8 ± 3.0 24.5 ± 2.7 25.0 ± 3.2*
Waist (cm) 84.6 ± 8.0 86.5 ± 7.3 82.6 ± 8.2*
WHR 0.86 ± 0.05 0.88 ± 0.04 0.84 ± 0.05*
Fasting plasma glucose (mmol/l) 5.6 ± 1.4 5.7 ± 1.4 5.4 ± 1.4*
Fasting insulin (μIU/ml) 11.2 ± 7.7 11.2 ± 8.5 11.3 ± 6.8
HOMA-IR 2.84 ± 3.03 2.93 ± 3.83 2.75 ± 1.88
Total cholesterol (mmol/l) 5.24 ± 0.91 5.14 ± 0.86 5.33 ± 0.96*
HDL cholesterol (mmol/l) 1.22 ± 0.31 1.14 ± 0.25 1.31 ± 0.35*
Triglycerides (mmol/l) 1.89 ± 1.38 2.13 ± 1.46 1.64 ± 1.26*
Systolic BP (mmHg) 130.8 ± 18.7 130.1 ± 17.5 131.5 ± 19.9
Diastolic BP (mmHg) 80.3 ± 12.3 80.5 ± 11.7 80.2 ± 13.0
Antidiabetic medication (%) 5.3 6.4 4.2
Antihypertensive medication (%) 16.6 14.3 19.0
Lipid-lowering medication (%) 4.6 3.7 5.5
Current smoking (%) 25.4 45.6 4.3*
History of CHD (%) 5.1 4.3 6.0
History of CVA (%) 3.0 2.9 3.2
CHD, coronary heart disease; CVA, cerebrovascular accident.
Data are means±SD and %.
*p < 0.05.
, only untreated patients.Metabolic Syndrome in Korean Adults
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TG levels were higher in men, but TC and HDL
cholesterol levels were higher in women.
However, SBP, DBP, fasting insulin level and
HOMA-IR showed no significant difference
between genders. Eight percent of women and
13.2% of men had diabetes, and 9.3% of men and
4.3% of women had IFG (data not shown).
Prevalence of the metabolic syndrome and its
components according to the modified WHO
criteria (Table 2)
The prevalence of the metabolic syndrome in
women was increased significantly according to
increasing age, but in men it did not differ with
age group. The prevalence in the 30-39 and 40-49
years groups was higher in men than in women,
but in the 50-59, 60-69 and 70-79 years groups was
similar between men and women.
The prevalences of dyslipidemia, hypertension,
IFG/DM and obesity were increased significantly
according to increasing age in both men and
women. However, the prevalence of dyslipidemia
in men was decreased significantly according to
increasing age. The prevalences of dyslipidemia
and IFG/DM were higher in men than in women,
but the prevalence of obesity was higher in
women. The prevalence of hypertension was not
different between men and women.
Prevalence of the metabolic syndrome and its
components according to the modified NCEP
criteria (Table 3)
The prevalence of the metabolic syndrome was
not different between men and women. It was
increased significantly according to increasing
age in women, but was not different by age
group in men. The prevalence in the 30-39 and
40-49 years groups was higher in men, but in the
50-59, 60-69 and 70-79 years groups was higher
in women.
The prevalences of abdominal obesity, high TG,
high BP and high glucose were increased signi-
ficantly according to increasing age in both men
and women. The prevalence of high TG in men
was decreased significantly according to increa-
sing age. The prevalence of low HDL cholesterol
was not different according to increasing age. The
prevalences of abdominal obesity and low HDL
cholesterol were higher in women than in men,
but the prevalences of high TG and high glucose
were higher in men. The prevalence of hyperten-
sion was not different between men and women.
Discrepancy of the metabolic syndrome between
the modified WHO and NCEP criteria
The prevalence of the metabolic syndrome
Table 2. Prevalence of the Metabolic Syndrome and its Components According to the Modified WHO Criteria
No. Met. Synd. Dyslipidemia Hypertension IFG/DM Obesity
men women men women men women men women men women men women
All* 627 603 21.8 19.4 53.7 38.6 43.7 42.0 23.5 14.5 58.8 64.4
30 - 39 years 101 48 18.8 10.4 59.4 25.0 24.8 8.3 11.9 4.2 47.5 43.8
40 - 49 years 168 157 21.2 9.6 66.7 27.4 33.3 30.6 21.4 7.0 58.3 51.0
50 - 59 years 196 226 24.0 20.8 57.7 40.7 41.3 49.1 26.0 13.3 59.2 66.8
60 - 69 years 140 150 22.1 20.0 43.6 45.3 50.7 54.0 26.4 16.0 56.4 78.7
70 - 79 years 22 22 22.7 36.4 40.9 54.5 68.2 68.2 31.8 31.8 72.7 81.8
IFG, impaired fasting glucose; DM, diabetes millitus.
Data are number or %.
*age-adjusted.
p < 0.05 between men and women.
p < 0.05 between age group.
§metabotic syndrome.Sung Hee Choi, et al.
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according to the modified NCEP criteria was
significantly higher than according to the WHO
criteria. The prevalence of obesity was slightly
higher in the WHO criteria, but the prevalence of
high BP was significantly higher in the NCEP
criteria.
The prevalence of the metabolic syndrome con-
sistent in both criteria was 13.9% in women and
17.4% in men (Fig. 1). However, 23.9% of women
and 17.5% of men had the metabolic syndrome
according to the NCEP criteria, but did not
according to the WHO criteria. 3.5% in women
and 5.1% in men with metabolic syndrome ac-
cording to the WHO criteria did not have it ac-
cording to the NCEP criteria.
DISCUSSION
We first applied the WHO criteria to assess the
prevalence of the metabolic syndrome and
compared this assessment with that obtained with
the NCEP criteria in Korean adults. The preval-
ence of the metabolic syndrome according to the
modified WHO criteria was 21.8% of men and
19.4% of women. However, according to the
modified NCEP criteria the prevalence was
increased 1.6 times (34.2%) in men and 2.0 times
(38.7%) in women.
In previous studies, the prevalence has varied
widely, primarily due to different definitions of
the syndrome or selection of various ethnic sub-
groups. In the ARIC study population, a combina-
tion of hypertension (blood pressure > 140/90 mm
Hg and/or the use of antihypertensive treatment)
and dyslipidemia (triglycerides > 2.26 mmol/l
and/or HDL < 0.9 in men and < 1.2 mmol/l in
Table 3. Prevalence of the Metabolic Syndrome and Its Components According to the Modified NCEP ATP III Criteria
Met. Synd. Obesity High TG Low HDLc High BP High Glc
men women men women men women men women men women men women
All* 34.2 38.7 38.9 62.1 47.2 32.4 34.4 47.6 61.9 59.1 23.5 14.5
30-39 years 25.7 18.8 28.7 37.5 58.4 18.8 30.7 50.0 40.6 25.0 11.9 4.2
40-49 years 39.3 28.0 32.7 46.5 64.3 21.7 42.9 47.1 53.6 49.0 21.4 7.0
50-59 years 38.3 40.3 35.7 67.3 52.0 36.3 34.7 40.3 58.2 63.7 26.0 13.3
60-69 years 31.4 47.3 33.6 82.0 38.6 35.3 36.4 46.0 70.7 76.0 26.4 16.0
70-79 years 36.4 59.1 63.6 77.3 22.7 50.0 27.3 54.5 86.4 81.8 31.8 31.8
Data are number or %.
*age-adjusted.
p < 0.05 between men and women.
p < 0.05 between age group.
Fig. 1. Discrepancy of the metabolic syndrome between
the modified WHO and NCEP criteria.Metabolic Syndrome in Korean Adults
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women) was observed in 10% of the subjects.
9 In
the OPERA study, the prevalence of the metabolic
syndrome varied depending on the definition
from 0.8 to 35.3%, being lowest in the control men
and women and highest in the hypertensive
men.
10
Applying the WHO definition to the population
from the Botnia study in Finland and Sweden,
about 10% of persons with NGT, 40% with IGT
and 85% with type 2 diabetes had the metabolic
syndrome, and the prevalence of the syndrome
was also very age-dependent and higher in men
than in women.
11 In the West Bank population
study, the age-adjusted prevalence of the meta-
bolic syndrome defined by the WHO workgroup
was 17%.
12 In our study, about 10% of subjects
with NFG, 50% with IFG and 70% with type 2
diabetes had the metabolic syndrome (data not
shown). Thus, the prevalence of the metabolic
syndrome in Korean adults according to the WHO
criteria was similar to that in Western countries.
In the US, the unadjusted and age-adjusted
prevalence of the metabolic syndrome as defined
by the NCEP ATP III report was 21.8% and 23.7%,
respectively.
13 In the present study, the prevalence
in Korean adults as defined by the modified
NCEP criteria was significantly higher than in
Western countries. Therefore, application of the
Western NCEP criteria without modification to
the Korean population may underestimate the
adults at risk.
The prevalence of the metabolic syndrome in
previous Korean studies has varied widely, from
5.2-28.6% in men and 2.4-27.8% in women (Table
4).
14-18 This large variation partly results from
different study design. In the Korea Medical
Insurance Corporation (KMIC) study, dyslipi-
demia and obesity were not included in the
criteria of the metabolic syndrome.
14 In the
Jungup study, the criteria of high triglycerides
were higher than those of other studies and
obesity was not included.
15 Thus, the prevalence
of the metabolic syndrome in these two studies
may have been underestimated.
Park et al. reported that the prevalence of the
metabolic syndrome as defined by the NCEP
Table 4. Prevalence of the Metabolic Syndrome in Korean Adults
Study Design
Samplin
g year
No. of subjects Age (mean) Criteria Prevalence (%)
This study
Health care
center
2001
1,230
(M 627/F 603)
30-79
(M 51.3/F 53.5)
WHO + BMI
NCEP + WC
M 21.8/F 19.4
M 34.2/F 38.7
Jee et al.
14
Nationwide
data
(KMIC)
1990
183,061
(M 115,200/F 67,861)
35-59
(M 44.7/F 42.3)
2 or more (HTN,
smoking, DM,
Hyperchol.)*
M 18.6/F 2.4
Kim et al.
15 Rural survey
(Jungup)
1996 1,018
(M 388/F 630)
40-
(M 61.3/F 60.8)
2 or more (IGT,
HTN, Dyslipid.)
M 12.8/F 19.6
Park et al.
16 Health care
center
2001
40,698
(M 26,528/F 14,170)
20-82
(M 41.4/F 41.1)
NCEP
NCEP + WC
NCEP + BMI
M 5.2/F 9.0
M 9.8/F 12.4
M 13.2/F 13.1
Kim et al.
17
Nationwide
survey
(KNHANES)
1998
6,147
(M 2,731/F 3,416)
25-79
(M 44.6/F 46.5)
NCEP + WC
NCEP + WHR
M 22.1/F 27.8
M 28.6/F 27.8
Park et al.
18
Nationwide
survey
(KNHANES)
1998
7,865
(M 3,572/F 4,293)
20-79
(M 43.9/F 44.5)
NCEP + WC M 20.1/F 23.9
KMIC, Korea Medical Insurance Corporation; KNHANES, Korea National Health and Nutrition Survey; WHO + BMI, BMI 25.0
kg/m
2; NCEP, original NCEP ATP III criteria; NCEP + WC, WC 90(M), 80(F); NCEP + WHR/BMI, criteria for abdominal obesity was
replaced with waist to hip ratio or body mass index.
*HTN, BP 140/90 mmHg, DM, FBS 126 mg/dL, Hyperchol, TC 240 mg/dL.
HTN, BP 140/90 mmHg, dyslipidemia, TG 200 mg/dL and HDLC<37(M) 45(F).Sung Hee Choi, et al.
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criteria with abdominal obesity criteria for Asians
was 9.8% in men and 12.4% in women; preval-
ences that were lower than ours.
16 The study
subjects were recruited from among the clients of
a health care center, as was the case in our study
design. The different results of the two studies
may have arisen from selection bias, which
implied that our subjects were older and less
healthy than those of Park et al.
In 1998, the first Korea National Health and
Nutrition Survey (KNHANES) was conducted,
and the nationwide prevalence of the metabolic
syndrome was reported recently.
17,18 The esti-
mated prevalence according to the NCEP criteria
of the present study was higher than that of
KNHANES, as our subjects were older (51.3 vs.
44.6 years) and more obese (BMI 24.5 vs. 23.2 kg/
m
2, WC 86.5 vs. 83.2 cm in men) than those of
KNHANES. Therefore, the prevalences of high
BP, high TG, low HDL of our results seem to have
been overestimated.
The discrepancies of the prevalence of the meta-
bolic syndrome in Korean adults were mainly
caused by the criteria of high BP and dyslipi-
demia, especially the low HDL cholesterol level of
the NCEP criteria. The prevalence of high BP as
defined by the NCEP criteria in this study was
about 1.5 times that of the WHO criteria. The
mean level of HDL cholesterol in this study was
44 mg/dL in men and 51 mg/dL in women,
which is the same as the results of a nationwide
survey.
17 In the US, the mean level of HDL cho-
lesterol was 45 mg/dL in men and 55 mg/dL in
women. So, the cut-off value to define low HDL
cholesterol (40 mg/dL in men and 50 mg/dL in
women) in the NCEP criteria is reasonable in the
US, but is higher than the general population in
Korea, especially in women. So, in the KNHANES
study, the prevalence of the metabolic syndrome
was higher than that of American whites.
17
3.5% of women and 5.1% of men had metabolic
syndrome according to the WHO criteria, but not
according to the NCEP criteria. These subjects
were more insulin resistant (HOMA-IR 4.4 ± 1.5
vs. 2.7 ± 5.5), had higher fasting glucose (6.0 ±
1.6 vs. 5.4 ± 1.1 mmol/L), were more obese (BMI
27.1 ± 2.7 vs. 25.8 ± 2.7 kg/m
2), had lower trigly-
cerides (1.9 ±1.3 vs. 2.6±1.6 mmol/L) and higher
HDL cholesterol (1.4 ± 0.4 vs. 1.0 ± 0.2 mmol/L)
than subjects of the metabolic syndrome with the
NCEP criteria only.
We acknowledge some limitations of this study.
We did not check urine albumin concentrations.
By urine stick test, the prevalence of albuminuria
above one positive was 2.4% of the total subjects.
We excluded microalbuminuria from the criteria
of the metabolic syndrome because of the low
prevalence of microalbuminuria in other studies.
Nevertheless, microalbuminuria has been a strong
predictor of cardiovascular morbidity and mor-
tality in several studies.
11,21-23 We assessed glucose
tolerance by only fasting plasma glucose, and did
not perform an oral glucose tolerance test.
Because of diagnostic discrepancy between fasting
glucose and oral glucose tolerance test, IGT and
type 2 diabetic patients may have been underes-
timated in this study.
We also acknowledge that these study subjects
were older and more obese than the general popu-
lation in Korea. The prevalence of the metabolic
syndrome in this study population may therefore
have been slightly overestimated.
In conclusion, the metabolic syndrome is seen
in about 20 - 40% of Korean adults. Its prevalence
has varied widely according to the criteria of its
definition. Thus, further studies are necessary to
define the criteria of the metabolic syndrome in
Korean adults.
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